Synthetic nanogel antibodies molecularly imprinted with the Spike S1 protein -ANTISPIKE

Project Manager: SR I. Dr. eng. Anamaria ZAHARIA () National Institute for Research & Development in Chemistry and Petrochemistry – ICECHIM, Bucharest

Funding: Executive Unit for the Financing of Higher Education, Research, Development and Innovation (UEFISCDI)

Programme: PN II- Human Resources Programme – Young research teams 2021

Project number: PN-III-P1-1.1-TE-2021-1239

Research domain – Pharmacology and pharmacogenomics (including drug discovery and design, drug delivery and therapy, toxicology)

Financing contract: Nr. 144/13.05.2022

Total funding of the contract: 450.000 RON

Period of project implementation: 13.05.2022 – 12.05.2024 (24 months)


Abstract

SARS-CoV-2 is a new coronavirus type and it is responsible for causing COVID 2019 in humans, with very high contagion rate all over the world. The viral entry of SARS CoV-2 is conferred by the presence of Spike S1 protein on the surface that can direct attachment and enter the plasma membrane of the human cell. The Spike protein through its location is a significant therapeutic target, and targetable using antibodies. Despite recent technological developments, effective and safe therapies are currently not available for treating the infected victims. Thereby, the general objective of the project targets the synthesis of synthetic nanogel antibodies molecularly imprinted with Spike S1 (MIP-SNAs) for recognizing and retaining coronavirus-originated Spike S1 proteins. In this respect, the MIP-SNAs are able to recognize and bond to the Spike S1 proteins, acting as nanogel caps, and thus inhibiting the activity of SARS-CoV-2 antigen to penetrate the human cells. Hence, ANTISPIKE holds significant influence upon the scientific community by new concepts and methodologies for ligand-free delivery systems as MIP-SNAs (short-term impact: scientific ISI papers and communications, and national patent claim) and by opening new research directions associated with the side-benefits of the research (like new immuno-therapies) as long-term impact. Implementation of this project will also bring specific scientific, economic and social benefits at the national and international level.


Objective:

The overall aim of the “ANTISPIKE” project refers to developing original, cost-effective and biocompatible ligand-free nanogel delivery systems that can be used as potential treatment for patients affected by COVID-19.

Estimated ResultsANTISPIKE holds significant influence upon the scientific community by new concepts and methodologies for ligand-free delivery systems as MIP-SNAs: 3 scientific ISI papers sent for publication and 3 scientific communications, one national patent claim, website of project “ANTISPIKE” and by opening new research directions associated with the side-benefits of the research, like new immuno-therapies. Implementation of this project will also bring specific scientific, economic and social benefits at the national and international level.